Gross, Neil; Carey, John; Hamilton, Joan. "Quiet Strides in the War on Cancer" Business Week. February 6:150, 1995.
Lidbeck, A.; Allinger, U. G.; Orrhage, K. M.; Ottova, L.; Brismar, B.; Gustafsson, J. A.; Rafter, J.; Nord, C. E. "Impact of Lactobacillus Acidophilus Supplements on the Fecal Microflora and Soluble Fecal Bile Acids in Colon Cancer Patients," Microbial Ecology in Health and Disease. 4:81-8, 1991.
Lidbeck, A.; Nord, C. E.; Gustafsson, J. A.; Rafter, J. "Lactobacilli, Anticarcinogenic Activities and Human Intestinal Microflora," Eur J Cancer Prev. 1:341-353, 1992.
Shahani, K. et al, Antitumor activity of fermented colostrum and milk 01-May-83 - Investigated the effect of feeding fresh colostrum and colostrum cultured with either L. acidophilus, L. bulgaricus or yoghurt starter on the proliferation of ascites tumor cells.
Parodi, PW. Cows' milk fat components as potential anticarcinogenic agents. Journal of Nutrition 127(6):1055-1060 (1997). Including dairy products in the diet has been shown to lessen the chance of developing cancer. One of the ways dairy products accomplish this is through the anticarcinogenic properties of several milk fats, including conjugated linoleic acid (CLA), sphingomyelin, butyric acid and ether lipids. Cows also have the ability to absorb anticarcinogenic compounds, such as beta-carotene, beta-ionone and gossypol, from their feed and include them in their milk.
Parodi, PW. Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. J Dairy Sci. 1999 Jun;82(6):1339-49.. CLA in even small amounts has a potent anticarcinogenic effect, as does sphingomyelin. Other components of milk with anticarcinogenic activity include butyric acid, ether lipids, beta-carotene and vitamins A and D.
Pizza, G, et al. A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy 9(1-3):123-132 (1996). Transfer factor (PRPs) increased the survival rate of stage D3 prostate cancer patients.
See, D, et al. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunological Investigations 31(2):137-153 (2002). PRPs are known to increase the production of both TNF-alpha and NK cell activity. This treatment strategy has shown promise in the treatment of terminal cancers.